Clinical trial
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial
NCT04875702 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- February 22, 2024
- Completion date
- October 31, 2028
- Enrollment
- 650 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.